Insider buying last 90 days
No open-market insider purchases were filed for ALNY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ALNY insider filing, plotted on the chart in Gekko.Open ALNY in Gekko
NASDAQ: ALNY
Alnylam Pharmaceuticals (ALNY) Stock Analysis & Forecast
Nov 4 close
$161.08+1.19 (+0.7%)
Gekko Brief
AI summaryOct 28 closeThis week's news centers on early clinical results for brezosiran, Alnylam's investigational RNA interference therapy for Huntington's disease, with Phase 1b data showing dose-dependent reductions in mutant huntingtin of up to 83% and a reportedly encouraging safety profile, alongside plans to begin a placebo-controlled pivotal study. Analyst reaction followed: UBS cut its price target from $550.00 to $354.00 while maintaining a Buy rating, and Citi reiterated a Buy rating with a $320 target. Separately, Alnylam's lobbying spending rose to $730,000 in the third quarter amid Medicare drug pricing and tariff discussions.
Alnylam shares closed at $232.40, up 2.5% on the day, though the stock remains below both its 50-day average of $239.15 and its 200-day average of $287.47, with the 50-day below the 200-day. Over the past month shares are down 8.5%, though the 3-month return stands at 13.1%. The GekkoIndex reads 57.6, placing the stock in the Neutral zone, while the price sits 19.7% below the Gekko Fair Value of $289.52.
Alnylam reports earnings on 29 October 2026 before the open, falling within the next 20-trading-day window; the prior quarter saw an EPS miss against a $1.44 estimate with a -28.3% reaction, against a backdrop of 6 beats in the last 8 quarters. In the last 30 days there has been 1 unusual options signal, with call premium of $708,400 against put premium of $205,530. Seasonality over 5 years shows a 0.3% average 20-day return from this point, rising in 3 of those years. Consensus among 24 firms stands at 19 buy and 5 hold ratings, with a consensus target of $367.78.
Written by AI from the Oct 28, 2026 close and checked automatically against the figures on this page.
Alnylam Pharmaceuticals price vs fair value
Close $161.08200-day averageGekko Fair Value $259.23
Alnylam Pharmaceuticals quick facts
- Market cap
- $21.57B
- P/E ratio
- 8
- Forward P/E
- 12.9
- EPS, TTM
- $19.80
- Revenue, TTM
- $5.01B
- Profit margin
- 52.8%
- Dividend yield
- —
- Beta
- 0.44
- Volume
- 3.47M avg 2.56M
- 1-year return
- −62.9%
- Typical daily move
- ±7.5%
- Typical 20-day move
- ±7%
- 50-day average
- $231.83
- 200-day average
- $282.50
- Next earnings
- Feb 11 before open
- Shares outstanding
- 133.9M
Alnylam Pharmaceuticals swing-trade checklist
Alnylam Pharmaceuticals scores 5 supportive, 0 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive0 mixed1 headwind
- Trendheadwind
Below 50 and 200-day
Close $161.08 is below the 50-day ($231.83) and 200-day ($282.50) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
80.3, Buying
Reading 80.3 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
37.9% below
Price is 37.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 98 days
Next report Feb 11, 2027, 98 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+1.9% on average
From this point in the calendar, the next 20 trading days averaged +1.9% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Alnylam Pharmaceuticals stock chart and price history
Alnylam Pharmaceuticals closed at $161.08 on Nov 4, 2026, −62.9% over the past year, inside a 52-week range of $156.00 to $479.79.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −28.1%
- 3 months
- −25.5%
- 6 months
- −46.8%
- 1 year
- −62.9%
The full ALNY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ALNY in Gekko
Follow Alnylam Pharmaceuticals through every session
Put ALNY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ALNY in GekkoFree for 7 days. No credit card required.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals works in medicine built around RNA interference, a technique used to silence disease-causing genes. The company turns this science into treatments for conditions such as inherited genetic disorders, cardio-metabolic disease, liver infections, and disorders of the nervous system and eyes. It has brought three therapies to market: ONPATTRO for nerve damage linked to hereditary transthyretin amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for a rare kidney condition called primary hyperoxaluria type 1.
Alongside these approved products, Alnylam runs a pipeline of experimental treatments targeting conditions including hepatitis B, high cholesterol, hemophilia, hypertension, liver disease linked to AAT deficiency, and NASH, with several candidates in later-stage trials. Much of this work is carried out through partnerships, including research alliances with Regeneron and Sanofi Genzyme, plus additional licensing arrangements with companies such as Novartis, Vir Biotechnology, Dicerna, Ionis and PeptiDream.
The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Its shares are listed on the NASDAQ under the ticker ALNY.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- alnylam.com
Alnylam Pharmaceuticals GekkoIndex: the smart money zone
Alnylam Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 80.3, in the Buying zone, up 22.7 points over five sessions.
80.3Buying
Up 22.7 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying (current zone) | 45 | +0.2% | −4.3% |
| Accumulation | 284 | 0.0% | −0.3% |
| Neutral | 322 | +0.6% | +4.4% |
| Distribution | 33 | −0.5% | −0.8% |
| Selling | 13 | +4.0% | +0.6% |
Average ALNY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.0% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the ALNY price, zone by zone.Track ALNY in Gekko
Is Alnylam Pharmaceuticals stock overvalued? Gekko Fair Value
Alnylam Pharmaceuticals trades 37.9% below Gekko Fair Value of $259.23, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Alnylam Pharmaceuticals shares are worth, recalculated every trading day.
$259.23
Gekko Fair Value, Nov 4, 2026
37.9% Undervalued
At the end of Aug 2026 the price was 27.5% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ALNY in Gekko
Alnylam Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Alnylam Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ALNY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ALNY, plotted on the chart in Gekko.Open ALNY in Gekko
Buybacks
Alnylam Pharmaceuticals has been buying back its own shares.
- Bought back, year ended Dec 31, 2018
- $3.47M
- As a share of market cap
- 0.02%
From company filings.
Unusual options activity last 30 days
1signal, 78% of the flagged premium in calls.
Latest: Bullish flow on Oct 20, $914K in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold ALNY.
0added2opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Alnylam Pharmaceuticals earnings: next date and track record
Alnylam Pharmaceuticals reports on Feb 11, 2027, before the open (98 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Feb 11, 2027
Expected before the open, 98 days away
- EPS estimate
- $1.72
- Revenue estimate
- $1.53B
7 of 8reports beat the EPS estimate
±11.3%average move across the report
1 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 29, 2026 AI summary
- What they said
- Alnylam reported Q3 product revenues of ~$1.3 billion, up 52% year-over-year, driven by AMVUTTRA uptake. Total TTR revenues reached $1.15 billion, representing ~60% YoY growth. Management acknowledged unsatisfactory underlying demand growth despite commercial investments. Pipeline highlights include nucresiran TRITON-CM enrollment expansion to ~2,250 patients and encouraging early brezosiran data in Huntington's disease.
- Guidance
- Full year outlook revised downward reflecting slower-than-expected demand conversion from expanded sales force. Nucresiran ATTR cardiomyopathy launch timeline remains 2030, contingent on positive TRITON-CM results and regulatory approval. Pivotal brezosiran study targeting 2027 initiation pending regulatory alignment.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $16.26 est $1.66 | $1.46B est $1.43B | −29.0% |
| Jul 30, 2026 | −$0.52 est $1.44 | $1.29B est $1.32B | −28.3% |
| Apr 30, 2026 | $1.99 est $1.47 | $1.17B est $1.12B | −1.7% |
| Feb 12, 2026 | $1.25 est $1.24 | $1.10B est $1.15B | −2.4% |
| Oct 30, 2025 | $2.90 est $0.56 | $1.25B est $959.4M | −5.3% |
| Jul 31, 2025 | $0.32 est −$0.54 | $773.7M est $662.9M | +18.2% |
| May 1, 2025 | −$0.01 est −$0.89 | $594.2M est $585.1M | −1.5% |
| Feb 13, 2025 | $0.06 est −$0.14 | $593.2M est $582.6M | −3.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Alnylam Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Alnylam Pharmaceuticals is $302.48, +87.8% from the last close, from 25 firms rating the stock in the last 90 days.
$302.48consensus 12-month target, +87.8% from the last close
Now $161.08Avg $302.48
Low $220High $455
Each firm’s latest rating in the last 90 days: 25 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Truist Financial | $225 | +39.7% |
| Nov 2 | Canaccord Genuity | $323 | +100.5% |
| Nov 2 | Barclays | $380 | +135.9% |
| Oct 30 | Chardan Capital | $375 | +132.8% |
| Oct 30 | Bernstein | — | — |
−4.3%average 20-day move after past Buying readings
+1.9%average move over the next 20 trading days in the last 5 years
±7.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Alnylam Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Alnylam Pharmaceuticals averaged +1.9% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.9% | 3 of 5 |
| Next 10 trading days | −1.2% | 2 of 5 |
| Next 15 trading days | −1.7% | 3 of 5 |
| Next 20 trading days | +1.9% | 3 of 5 |
| Next 30 trading days | +2.5% | 3 of 5 |
For scale, ALNY’s typical 20-trading-day move in either direction is about 7%.
Alnylam Pharmaceuticals market cap and key statistics
Alnylam Pharmaceuticals’s market cap is $21.57B, with a P/E ratio of 8 and revenue of $5.01B over the last twelve months.
Valuation
- Market cap
- $21.57B
- P/E ratio
- 8
- Forward P/E
- 12.9
- EPS, TTM
- $19.80
- Gekko Fair Value
- $259.23
Trading
- Volume
- 3.47M
- Avg volume, 20 days
- 2.56M
- 52-week high
- $479.79
- 52-week low
- $156.00
- Shares outstanding
- 133.9M
Financials
- Revenue, TTM
- $5.01B
- Profit margin
- 52.8%
- Return on equity
- 138.1%
- Quarterly earnings growth, YoY
- +633.0%
Risk and income
- Beta
- 0.44
- Typical daily move
- ±7.5%
- Typical 20-day move
- ±7%
Alnylam Pharmaceuticals stock news this week
Coverage of Alnylam Pharmaceuticals this week reads neutral: 3 positive, 6 neutral and 0 negative headlines.
- Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial LeadershipBusiness Wire, Nov 4
- Can Alnylam Pharmaceuticals (ALNY) Justify Its Price After A 62% Fall?Simply Wall St, Nov 4
- Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026Business Wire, Nov 3
- Form 4 Alnylam Pharmaceuticals Inc For: 2 November By Investing.comInvesting.com Nigeria, Nov 3
- Barclays maintains Alnylam Pharmaceuticals at Overweight, lowers price target to $380 from $450TradingView, Nov 2
- Should You Buy The Dip In Alnylam Stock?Trefis, Nov 2
Alnylam Pharmaceuticals peers
Alnylam Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Distribution | 27.7% above |
| JNJJohnson & Johnson | Neutral | 1.7% below |
| ABBVAbbVie | Neutral | 26.5% above |
| MRKMerck | Neutral | 8.6% below |
| AZNAstraZeneca | Distribution | 34.1% below |
| PFEPfizer | Neutral | 4.1% below |
A peer links to its own page where one exists.
Alnylam Pharmaceuticals stock FAQ
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $21.57B at the Nov 4, 2026 close of $161.08, with 133.9M shares outstanding. The shares trade on a P/E ratio of 8.
What is the Alnylam Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Alnylam Pharmaceuticals is $302.48, +87.8% from the last close. Of the 25 firms that rated the stock in the last 90 days, 17 rate it a buy, 8 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Alnylam Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Alnylam Pharmaceuticals is undervalued: the Nov 4, 2026 close of $161.08 is 37.9% below Gekko Fair Value of $259.23. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Alnylam Pharmaceuticals report earnings next?
Alnylam Pharmaceuticals is expected to report on Feb 11, 2027, before the market opens (98 days away). Analysts expect earnings of $1.72 per share on revenue of $1.53B. Alnylam Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 11.3% on average across the report.
What is Alnylam Pharmaceuticals’s 52-week high and low?
Alnylam Pharmaceuticals’s 52-week high is $479.79 and its 52-week low is $156.00; it closed at $161.08 on Nov 4, 2026, −62.9% over the past year. Over the last five years the shares peaked at $495.55 on Oct 20, 2025.
Is Alnylam Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Alnylam Pharmaceuticals?
Gekko flagged 1 unusual options signal in Alnylam Pharmaceuticals over the last 30 days, with $708K of flagged premium in calls and $206K in puts. The latest, bullish flow, was on Oct 20, 2026 with $914K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Alnylam Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.